• More than half of Americans have attended a music festival, indicating lucrative potential for music and art destinations
• GTVH recently closed on the acquisition of ABI Create, a premier event-management and production company
• With the invaluable resources ABI Create brings to the table, the future of Destino Ranch looks more promising than ever

With Coachella still fresh in music lovers’ memories, it’s only natural to look at what other amazing music festivals might be looming in the future. Destino Ranch comes to mind. A new project focused on becoming an international destination where nature and technology combine to create unforgettable experiences such as outstanding music festivals, Destino Ranch is being developed by Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment.

Officially called the Coachella Valley Music and Arts Festival, Coachella is held over two weekends at the Empire Polo Club in Indio, California, in the Coachella Valley in the Colorado Desert. The event traditionally features an array of musical artists from different music genres, including rock, pop, indie, hip hop and more; the festival also includes art installations and sculptures.

This year, Coachella saw record attendance, with organizers reporting an estimated 300,000 people flocking to Indio (https://ibn.fm/Vr1u8). In addition, Coachella’s revenue is impressive, bringing in $115 million collectively from ticket, food and beverage sales and generating around $700 million for the local economy in Indio and surrounding cities each year (https://ibn.fm/Z8IJc).

There’s definitely an eager audience for events such as music and art festivals. In fact, a Marketing Chart study reported that “overall, roughly one-third (34%) of American adults surveyed report having been to more than one music festival, while an additional fifth (20%) say they’ve been once. As such, some 54% of U.S. adults have been to at least one music festival” (https://ibn.fm/mxLB2).

Clearly, Golden Triangle Ventures and Lavish Entertainment are on to something. Most recently the company took a significant step forward in the development of Destino Ranch with the acquisition of ABI Create, a premier event-management and production company (https://ibn.fm/XPvbI). Founded by Marco Antonio Moreno, who was recently named president and COO of Lavish Entertainment, ABI Create has delivered high-quality productions for a range of large-scale installations at major music festivals, sporting events and conventions across the United States, including the NFL Super Bowl, San Diego and New York Comic Con events, EDC and Camp EDC, Bonnaroo Music Festival, the Waste Management Phoenix Open, Arnold Palmer Invitational, Burning Man and more.

The completed acquisition will transition ABI Create into a wholly owned subsidiary of Lavish Entertainment, strengthening Lavish’s position in the entertainment industry through ABI’s well-known reputation and proven track record of executing high-level projects. Headquartered in Las Vegas, ABI’s comprehensive suite of services includes event organization, management, production, logistics, site planning, permitting, construction, contracting, custom design and fabrication.

With the invaluable resources ABI Create brings to the table, the future of Destino Ranch looks more promising than ever. With access to nearly 22,000 visitors traveling through the area every day, the ranch could quickly become a modern art and music festival mecca. In fact, current plans call for the destination location to include an immersive, world-class art installation gallery with rotating exhibits as well as a large-scale music venue with state-of-the-art staging and production, all carefully designed to complement the beautiful natural attributes of the surrounding Mojave Desert.

“This acquisition of ABI Create sets the stage for us to begin showcasing all other synergistic divisions within Lavish that will support all resources, relationships and partnerships within the ABI portfolio of offerings,” said Steffan Dalsgaard, CEO of Golden Triangle Ventures. “Our goal is to develop ABI into a one-stop-shop, event-management business within Lavish that will hold a complete suite of event management and development services. This aims to complement all internal projects and productions and will potentially support outside business opportunities that can provide fundamental synergies to our ultimate plan of building a complete entertainment enterprise.”

Golden Triangle Ventures is a multifaceted consulting company that operates as a parent business pursuing ventures in the health, entertainment and technology sectors, as represented by the three-point golden triangle, along with other sectors that provide synergistic value to these three core divisions. The company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services.

For more information, visit the company’s website at www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

• SenesTech’s Evolve(TM) Soft Bait has been proposed to be used in New York City to control its growing rat population
• In a bill tabled by Upper West Side Council Member Shaun Abreu, the city will explore contraception for rats and will start with a 10-block area
• SenesTech’s CTO notes that the city should see close to complete elimination of the population in 12-18 months, not by just controlling the death rate, but by controlling the birth rate as well
• For SenesTech, this move helps affirm the superiority of its products. In addition, it serves as a sign of even bigger things to come

On Thursday, April 11, Flaco, an escaped zoo owl, was found dead with raised levels of rodenticide in his system in New York City, having consumed poisoned rats for sustenance. This was a wake-up call, highlighting the ineffectiveness of the current approach to controlling the city’s rat population and its cost to pets, wildlife, and birds of prey (https://ibn.fm/aF3pC). As a result, the event prompted involved parties to explore alternative, more effective, and more humane approaches to controlling this rat problem, with contraceptives proving to be the viable option.

SenesTech (NASDAQ: SNES), a rodent fertility control product and service provider, and the inventor of the only EPA-registered contraceptive for male and female rats, has been rapidly growing with its unique rodent control solutions, defined by its two main offerings – ContraPest(R) liquid, and Evolve(TM) Soft Bait, both of which have demonstrated impressive results in controlling pest populations through fertility control. The city of New York is exploring the use of Evolve, owing to its shelf life, safety profile and overall effectiveness.

Studies have shown that two rats alone can multiply to 15,000 in just one year. While poisoning and controlling their death rate has proven ineffective and dangerous for other animals, contraception is showing to be an excellent option to explore, particularly since, for a controlled population, one can achieve complete elimination in 12-18 months.

“If you’ve gotten the whole population on birth control, you should see close to a complete elimination of that population in 12 to 18 months. You’re not controlling the death rate. You’re controlling the birth rate,” noted Dan Palasky, SenesTech’s Chief Technical Officer (https://ibn.fm/PReR4).

With the introduction of a new bill by an Upper West Side Council Member, the city is set to, hopefully once and for all, deal with the rat menace that has posed a challenge for every generation of New Yorkers. Various approaches have been explored, from the hiring of a “rat czar” in 2023 to the push to put trash out in boxes as opposed to bags to reduce the amount of food served up to rats (https://ibn.fm/PjiwW). While it holds true that rodents can never be eradicated, contraception is a viable option in managing their population, all within a reasonable timeline. This is achieved without the risk of poisoning other animals, as was the case with Flaco.

“Rat birth control is a promising non-toxic solution to remediating heavily infested areas without dumping lethal poisons all over our city’s streetscape,” noted Shaun Abreu, an Upper West Side City Council Member.

“We can’t poison our way out of the rat problem, but we can certainly do a lot of damage trying,” he added.

Abreu’s pilot program is proposed to start with a 10-block area, with a six-month study to gain a baseline understanding of rodent populations. This will then be followed by six months of birth control. SenesTech is optimistic that its Evolve Soft Bait will yield impressive results over that period, highlighting the product’s overall efficacy while stamping the company’s position as a leader in its space. Already, the company has seen major interest in its Evolve product, and this move by the city of New York is seen as affirming the product’s superiority while serving as a sign of even bigger things to come.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem
• Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024
• GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path
• The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings it closer to offering a tolerable oral delivery option for diabetes treatment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recognizes the tremendous potential in the treatment of type 2 diabetes and obesity, and looks to address it through its patented DehydraTECH(TM) drug delivery technology that offers improved delivery of bioactive compounds. The confidence in its technology, as evidenced by the success of previous clinical studies, has allowed it to double down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. The company is optimistic that the studies will yield positive results, not just in the potential treatment of diabetes but also in weight management, which has been directly linked to diabetes.

According to the Centers for Disease Control and Prevention (“CDC”), more than one in three Americans today are at increased risk for type 2 diabetes. This represents about 98 million Americans, with 81% not knowing they are at such a risk (https://ibn.fm/VG8YI). Studies showed a massive spike in overall incidences of type 2 diabetes between 2002 and 2018, with one of the main cited risk factors being obesity. The CDC noted that of those diagnosed with the condition, 89.8% of them were overweight or obese, as defined by a body mass index (“BMI”) of 25 kg/m2 or higher. This was further compounded by physical inactivity, with 31.9% of those diagnosed reporting getting less than 10 minutes a week of moderate or vigorous activity (https://ibn.fm/3Ass4).

In March, Lexaria announced details of its upcoming 12-week animal study WEIGHT-A24-1 that will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination (https://ibn.fm/TIcIT). Results will guide additional human investigations.

The company recently received independent third-party ethics review board approval for its GLP-1 human pilot study #2, seeking to explore the oral delivery of GLP-1 drugs. For Lexaria, this marks a significant milestone that brings it closer to offering a more effective and tolerable oral delivery option for diabetes treatment and weight loss management (https://ibn.fm/CyRPR).

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO.

“I am excited about this study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1,” he added.

Previous Lexaria studies have demonstrated that DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms. Already, GLP-1R agonists have been shown to penetrate the brain and activate a subset of GLP-1R-expressing neurons in the arcuate nucleus to produce weight loss. With the upcoming studies, Lexaria looks to evidence that DehydraTECH processing of GLP-1 drugs can enable even faster penetration into brain tissue, ultimately improving overall efficiency in weight loss and blood sugar control. Its management is optimistic that it will replicate the success of previous studies and looks forward to kickstarting the undertaking.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The growing call for court-administered electronic monitoring services remains, as evidenced by a recent deadly Pacific Northwest domestic violence case in which a judge had previously denied a victim’s petition for requiring the suspect to wear an ankle monitor
• Israel-based SuperCom Ltd. has dedicated its suite of PureSecurity products to help governments economically track and monitor individuals at risk for initiating new dangerous situations
• The company has focused its recent efforts on the North American market, while also making inroads in Europe where it recently received over $5 million in sales orders that it will fulfill over the next few months
• SuperCom’s recently announced financial reports highlight the company’s growing success at building its gross margin, revenues, and profits, including a reported 2,350 percent increase in EBITDA

A series of new orders for electronic monitoring technology to bolster European governments’ security infrastructure is strengthening the position of SuperCom (NASDAQ: SPCB) in the EM market.

The recent sales orders for SuperCom’s PureSecurity Suite of products amount to more than $5 million in revenues, orders that the growing electronic-monitoring (“EM”) security solutions provider expects to fulfill within the next three months.

“We are pleased to continue our collaboration with European government customers, further solidifying our dedication to enhancing public safety through our innovative products and solutions,” SuperCom President and CEO Ordan Trabelsi stated in a news release about the requisitions (https://ibn.fm/hqgCG). “This demonstrates the continued validation of our cutting-edge technology, our steadfast dedication to project delivery, and the invaluable relationships we’ve cultivated with our discerning customers.”

SuperCom is celebrating its growth after recently releasing its financial reports for the Q4 period and the year-end results for 2023. The financial reports showed the company’s gross margin grew to 41.4 percent, its EBITDA grew by 2,350 percent and gross profits rose 60 percent (https://ibn.fm/eycFr).

The company offers an end-to-end electronic monitoring solution with state-of-the-art GPS tracking in real time, secured communication and other monitoring technologies.

The PureProtect and PureOne products, which were rolled out during the year, provide improved protection to families suffering from domestic violence and an all-in-one GPS tracking ankle bracelet monitoring solution. The products have the potential to save lives in a society where domestic conflicts too often turn violent.

A Washington state domestic violence case that gained the attention of Pacific Northwest residents in late April (https://ibn.fm/vBH3L) served as a very recent example of the concerns these cases bring and the need for technological solutions to provide people with protection. Following the kidnapping of a young child and the death of two women, media reports noted one of the victims had sought a court order requiring the suspect to wear an electronic ankle monitor under the provisions of the Tiffany Hill Act, but the court denied the request (https://ibn.fm/erpBj).

SuperCom’s solutions also supports alcohol and drug substance treatment program monitoring, house arrest monitoring, and inmate monitoring. The monitors are easily concealable to reduce concerns about stigmatizing their wearers and include an ultra-lightweight base station with long battery life.

“Since 2018, SuperCom has secured over 50 new multi-year government projects. Our strong growing reputation as a premium provider of electronic monitoring solutions and services enhanced our market position with each new customer win,” Ordan said in a discussion of the year-end financial report (https://ibn.fm/fTjDu).

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

Attended by thousands of people worldwide, Finovate conferences are recognized as exclusive events, providing unmatched networking and growth opportunities within the fintech industry. Fintech leaders, entrepreneurs, innovators, senior bankers, investors and financial institutions are all invited to attend the Finovate Spring event being held on May 21-22, 2024, in Marriott Marquis San Francisco, San Francisco, CA. FinovateSpring 2024 is the much-awaited showcase of technology innovations in the financial and banking sectors.

Experience the future of finance with FinovateSpring 2024, a transformational event featuring a dynamic lineup of industry leaders who will share valuable insights into the future of finance and technology. Organizational speakers for the event include J.P. Morgan, Cornerstone Advisers, Charles Schwab, U.S. Bank, BNY Mellon, HSBC, University of California, Women in Payments, Wells Fargo, Cota Capital & more.

Innovation in the Finance Landscape

FinovateSpring serves as a catalyst of innovation, redefining finance with creativity, collaboration, and customer-centricity. This celebrated event provides startups and established businesses with a platform to showcase the latest innovations and unique solutions shaping the finance industry. The event will feature innovative product demos, showcasing the latest concepts and technologies in the finance industry. From AI-driven payment solutions to blockchain-powered banking, the unique solutions provide a glimpse into a fast developing and smarter financial era.

FinovateSpring is a unique opportunity for individuals looking to connect with like-minded visionaries to unlock new possibilities. As a hub for inspiration and creativity, the event is a perfect place to meet industry leaders and attend dynamic interactive panel discussions. Experts will share their perspectives on the evolving finance trends that will shape the future of finance. They will also provide unique solutions to tackle persistent challenges and drive innovation forward.

Registration for FinovateSpring 2024 is now open.

To learn more, please visit https://ibn.fm/cMczz

Date: May 18-19, 2024
Venue: Plaza Mayor, Medellin Colombia

ZJ Events brings BizCann Expo to Latin America, hosting the BizCann Expo 2024 in Medellin, Colombia, May 18-19, 2024. This event promises to boost cannabis investments and offer phenomenal cannabis business avenues in the region. The BizCann Expo 2024 conference offers cannabis traders, entrepreneurs, legislators, enthusiasts, and influencers, two days of networking, innovation, business, and education on the cannabis industry.

The BizCann Expo 2024 is a premier event that will connect the leading American cannabis markets for better opportunities. It will boost cannabis trade by offering a networking platform to all the cannabis businesses from all segments. 30+ eminent speakers of the industry will present insightful sessions covering the latest trends, hurdles, legislations, regulations, as well the innovations in this field.

BizCann Expo 2024 has partnered with well-known brands, from plant touching, non-plant touching, as well as ancillary services in the canna industry. The wide gamut of speakers comprises of manufacturers, professionals, service providers, legislators, software and accounting wizards, all catering to the cannabis industry.

The attendee list consists of growers, entrepreneurs, C-level executives, accountants, legal advisors, investors as well as newbies developing a foothold in the Latin American cannabis industry. Attendees can connect with the industry people and build their own cannabis community, and will also gain insights into the legal and licensing aspects of business. During the networking sessions, they can connect with industry veterans and peers to establish long-term business ties across the American landscape.

With its proximity to the US, Colombia offers the perfect venue for the expo. In addition, Medellin has great connecting facilities, a favourable legislation framework, and a vibrantly rich culture and history.

To know more, please visit https://ibn.fm/HqJFj.

• Btab Ecommerce and Integrated Wellness Acquisition Corp recently signed an LOI, to initiate a business combination, aiming for a process completion during the second half of 2024
• Completion of the transaction is contingent upon various factors including due diligence, regulatory approvals, and approval by both companies’ boards and stockholders
• Btab provides online technology affordable to the small and medium size online businesses that resell Btab’s proprietary products and third party products, including product supply, marketing platforms, physical showrooms, order and product return fulfillment, and after-sales support
• The global e-commerce market, estimated at $8.8 trillion in 2024, is projected to reach $18.81 trillion by 2029

Btab Ecommerce Group (OTC: BBTT), an ecommerce company, and Integrated Wellness Acquisition Corp (NYSE: WEL), announced in February 2024 the signing of a Letter of Intent (“LOI”) for a proposed business combination. This agreement will result in Btab acquiring control of WEL, with Btab valued at an initial enterprise value of $250 million (https://ibn.fm/1Lqwi).

The LOI outlines terms for the exchange of common and preferred shares between WEL and Btab, pending negotiation and signing of a definitive agreement. Btab, which operates globally, sees this partnership as a catalyst for its expansion plans in Europe, the Americas, and Asia.

“We are excited to announce this LOI with WEL and look forward to concluding the definitive agreement and closing the transaction as soon as feasible,” said Btab’s CEO, Binson Lau. “We believe that the capital raise contemplated in connection with this transaction will enable BTAB to accelerate its growth strategy as we seek to expand our reach into Europe, the Americas, and Asia.”

Suren Ajjarapu, CEO of Integrated Wellness, said the transaction will create, for WEL investors, the opportunity to participate in BTAB’s expected growth. “We look forward to finalizing the definitive agreement in the weeks to come.”

Completion of the transaction is contingent upon various factors including due diligence, regulatory approvals, and approval by both companies’ boards and stockholders. Additional details will be disclosed upon execution of a definitive agreement, with the Transaction expected to finalize in the second half of the year.

Btab comprehensive solutions to the small and medium online businesses that resell Btab’s proprietary products and third-party products include product supply, marketing platforms, physical showrooms, order and product return fulfillment, and other after-sales support.

The company aims to become a global leader in supplying products to small business, online resellers across the globe and to expand its reach across continents. Its platforms, like Btab Commerce and SocialSocial.Social, cater to manufacturers, wholesalers, and retailers, aiming to make online technology accessible to all online businesses that want to participate in and receive the benefits of the Btab platforms. Its Marketplace Australia and Aussie Markets platform provide social commerce solutions and online marketplaces for its proprietary and third-party products and services.

The global e-commerce market, estimated at $8.8 trillion in 2024, is projected to reach $18.81 trillion by 2029 (https://ibn.fm/n6Aus). Factors driving this growth include increasing internet penetration, smartphone usage, and the migration of businesses to online platforms. Btab aims to capitalize on this growth by empowering small and medium-sized businesses with its e-commerce solutions.

For more information, visit the company’s website at www.BtabCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to BBTT are available in the company’s newsroom at https://ibn.fm/BBTT

• HealthLynked achieved significant optimization in operational expenses, resulting in a 70% reduction in net loss for the fourth quarter and highlighting a period of strategic positioning for future growth
• HealthLynked’s full-year 2023 financial results mark technological advancements, with a focus on core technologies and profitability
• The company anticipates further performance improvements in the second half of 2024, positioning itself as a leader in healthcare technology

HealthLynked (OTCQB: HLYK), a leader in healthcare networking and technological innovation, recently announced its financial results for the fourth quarter and full year ending December 31, 2023. HealthLynked achieved a significant 70% reduction in net loss for the fourth quarter, highlighting a period of strategic advancements and focus on healthcare technologies plus networking capabilities (https://ibn.fm/ycgvs).

Dr. Michael Dent, CEO of HealthLynked said the recent launch of the pay app version 3.2.1 and the forthcoming integration of ARI mark significant milestones in the company’s mission to transform healthcare delivery and drive additional revenues. “Despite temporary staffing transitions, our focus on our core healthcare network and technological innovations position us for substantial growth and profitability,” Dr. Dent said. “We continue to grow our user base while integrating technology that improves patient care and the efficient exchange of medical information between doctors and patients.”

HealthLynked’s full-year 2023 financial results reflect investments in technological advancements that will accelerate revenue growth in our core technology application. Despite a modest 2% revenue decrease attributed to temporary staffing adjustments and the onboarding of new physicians, the release of the new pay app version 3.2.0, together with the integration of our Artificial Intelligence – ARI – into the HealthLynked app, present promising opportunities for core revenue growth.

Operational efficiency was notably improved with a 52% cut in operational losses and a 19% reduction in operating expenses, signaling HealthLynked’s commitment to financial stewardship. The strategic divestiture of ACO Health Partners bolstered financial restructuring, contributing $3.76 million and enhancing liquidity. A dramatic reduction in net loss to $1.01 million from $8.82 million in 2022 showcases the positive impact of strategic divestitures and operational efficiencies.

In the fourth quarter of 2023, revenue declined to $0.93 million due to temporary physician staffing adjustments, yet strategic initiatives led to a 73% reduction in operating loss and a 70% reduction in net loss, demonstrating resilience and adaptability amidst staffing transitions and emphasizing a commitment to long-term financial sustainability and growth. With a focus on core technologies and profitability, HealthLynked anticipates improved performance in the second half of 2024, positioning itself as a leader in healthcare technology.

The global patient-centric healthcare app market was valued at $18.65 billion in 2024. It is expected to reach 100.66 billion by 2029, growing at a CAGR of 40.11% during the forecast period (https://ibn.fm/FXFJn). The market is expected to grow because patients are more inclined to use apps to manage their chronic conditions, such as diabetes, hypertension, and more. The COVID-19 pandemic showed a positive impact on the market, and more apps have been launched in response to providing medical care to patients in more convenient methods.

The HealthLynked App is uniquely situated to take advantage of the explosive growth in that market as it is the only comprehensive network that addresses most of the problems in the healthcare industry.  As a result, demand for the app should be high as more features and services are added over time.

By concentrating on our core technologies and healthcare network, HealthLynked is poised to advance more profitably, continuing to innovate and lead in the healthcare sector.

HealthLynked maintains a steadfast commitment to advancing healthcare innovation through strategic focus and technological progress. The company deeply appreciates the ongoing support of its investors and stakeholders as it navigates these transitions and moves forward toward a future characterized by expansion, innovation, and improved healthcare results.

For more information, visit the company’s website at www.HealthLynked.com.

NOTE TO INVESTORS: The latest news and updates relating to HLYK are available in the company’s newsroom at https://ibn.fm/HLYK

Zevra Therapeutics (NASDAQ: ZVRA), a rare disease therapeutics company, uniquely combines data-driven techniques, patient needs and outside the box strategies while challenging moribund drug development protocols to bring new therapeutic relief to millions of people suffering with rare diseases. With a team of expert scientists, patient advocates, development strategists, commercialization specialists, and business development gurus – Zevra intends to become a global leader in developing and commercializing treatments for rare diseases that have limited or no therapeutic options. The company’s recent Letter to Stockholders reveals what looks like a launch code for success and suggests the company is on a fast track to drive value for all its stakeholders – patients and caregivers, stockholders, investors, and employees.

In the letter, Neil F. McFarlane, President and CEO, highlighted recent achievements and, importantly, outlined the vision for the company’s future. McFarlane began his tenure by instilling a couple of prime directives that have become guiding principles for the Zevra team. The first directive has become the company mantra, “What’s best for the patient?”, and patient outcomes now guide daily decisions. The second directive McFarlane instilled, “We must execute.”, drives value not just for patients but for all stakeholders – he believes that by defining a clear strategy, creating effective tactics to reach strategic objectives, then executing at the highest level will create and drive value, and help propel Zevra into global leadership in developing and commercializing rare disease therapeutics. Hard to argue with his directives, Zevra is fast making huge strides in reaching objectives.

Zevra has already made significant progress advancing its rare disease portfolio and made demonstrable progress in adroitly executing key strategic priorities. In November 2023, the company completed a shrewd, capital-efficient acquisition of Acer Therapeutics. That acquisition allowed Zerva to immediately start delivering value to patients by commercializing OLPRUVA(R) for treatment of urea cycle disorders (“UCDs”). UCDs are related to defects of enzymes involved in the urea cycle which can lead to high toxic features of ammonia-like irreversible brain damage, coma, and death.

Immediately after the acquisition, Zerva deployed a systematic strategy to build awareness with physicians across the country about OLPRUVA for people living with UCDs. In the three months since launch, Zerva’s team also engaged with over 90% of its customers. The company concurrently achieved meaningful growth in reimbursement coverage, from ~55% of U.S. covered lives at the time of acquisition, to now more than 70%.

The full commercial launch of OLPRUVA at the end of January 2024 was designed to provide scale and cost synergies to support and accelerate the launch and commercialization of arimoclomol to treat Niemann-Pick Disease. Affecting mostly children, Niemann-Pick is a group of rare genetic conditions that affect the body’s ability to break down and use fats, such as cholesterol and lipids, inside cells, and over time, the cells die worsening the function of the nerves, brain, and other organs. With no known cure and sometimes fatal, Zerva’s arimoclomol could be the lifeline so many children need.

Exemplifying the prime directives, the entire Zerva team put forth enormous effort to submit a comprehensive data set to the U.S. Food and Drug Administration (“FDA”) supporting the resubmission of the New Drug Application (“NDA”) for arimoclomol. In March, Zerva announced that the FDA had extended the review period for the NDA, resulting in a revised Prescription Drug User Fee Act (“PDUFA”) date of September 21, 2024.

Also in March, Zerva reported positive top-line data from its Phase 2 study of KP1077 in patients with idiopathic hypersomnia (“IH”). Initial results show that KP1077 is well tolerated and demonstrates early signs of differentiated and meaningful clinical benefits. Topline data from the completed trial are expected in the first half of 2024 and represent another potential Zevra commercial candidate.

Zerva fully intends to bring life-changing therapeutics to people living with rare diseases through expertise, elegant solutions, and transparent data narratives which have already produced a late-stage rare disease clinical pipeline and two partnered commercial products.

But blockbusters and breakthroughs don’t happen in a vacuum. It takes a dedicated and committed team of expert scientists, patient advocates, development strategists, commercialization specialists, and business development gurus with a proven record of bringing new therapies to patients…. and Zerva is loaded with talent.

Zerva is building a team of talented professionals committed to using science and data-driven development approaches to create and deliver new therapies to address critical and often overlooked unmet needs. Since announcing the strategic objective of becoming a leading rare disease company in the first half of 2022, Zerva has grown its team of skilled professionals through both recruiting and acquisitions, from a team of 24 to 81. It’s important to note that this personnel ramp-up includes the buildout of targeted customer-facing commercial and medical affairs teams with decades of experience in rare diseases. The company also added Adrian Quartel, M.D. as Zevra’s Chief Medical Officer, who brings more than 20 years of experience with a track record of success in clinical development, pharmacovigilance and medical affairs addressing the needs of the rare disease community. Such powerful commercial and clinical muscle are likely to really drive value and bode well for the future of the company.

Zevra Therapeutics leverages decades upon decades of collective experience in drug development and regulatory machinations to develop therapies faster and overcome challenging regulatory situations. Rare diseases may finally be reigned-in and held at bay by combining science, data, and patient needs with a team of dedicated professionals to create transformational therapies and bring life-changing therapeutics to millions of people living with rare diseases. Look for more exciting news from Zerva in the months to come.

For more information, please visit www.Zevra.com.

• 150+ Americans die every day from synthetic opioid (e.g. fentanyl) overdose
• Nutriband’s AVERSA(TM) Fentanyl technology is being developed as an innovative solution to abuse and misuse rates in prescription opioid patch medications
• Nutriband raised $8.4 million in a private placement to fund AVERSA Fentanyl through FDA Approval Process

Fentanyl addiction continues to devastate communities, with current treatment options facing limitations. However, as often happens in healthcare, innovation breeds hope with a new option on the horizon planning to seek FDA marketing approval.

The challenges related to the powerful painkiller (up to 50x stronger than heroin and 100x stronger than morphine) are well documented. According to the Centers for Disease Control and Prevention, more than 150 Americans die every day from overdoses related to synthetic opioids like fentanyl.

Nutriband (NASDAQ: NTRB) is looking to provide a much-needed new option for managing severe and chronic pain that requires the use of an opioid (https://ibn.fm/7AYt6). The Orlando-based company stated last month that it raised gross proceeds of $8.4 million towards the remaining clinical development of AVERSA(TM) Fentanyl and submission of its New Drug Application (“NDA”) with the U.S. Food and Drug Administration.

If approved, transdermal delivered AVERSA(TM) Fentanyl would become the world’s first opioid patch with abuse deterrent properties.

In its 2022 market analysis report of AVERSA(TM) Fentanyl, Health Advances, a leading healthcare consulting company, estimated peak U.S. sales of the new product between $80 million to $200 million.

The private placement was completed through the sale of 2.1 million shares of NTRB common stock at $4.00 per share, with each share purchased also entitling the purchaser to a warrant to purchase two more shares at a price of $6.43 per share, a sharp premium from the current price.

Products addressing chronic pain are the most advanced in Nutriband’s pipeline where its AVERSA(TM) platform technology is applicable. The company has added buprenorphine and methylphenidate to its development pipeline. Buprenorphine is also a medication used to treat opioid addiction, including addiction to heroin and other prescription painkillers. While very helpful because of its “ceiling effect,” meaning analgesia, euphoria, and respiratory depression plateau at high doses, buprenorphine still has the potential for abuse.

As it happens, the AVERSA(TM) abuse deterrent technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Other areas of focus for Nutriband’s transdermal expertise include attention deficit hyperactivity disorder (“ADHD”), Type 2 diabetes, and infertility. While those developments take shape, all eyes will be on the NDA filing with the FDA and what that can mean for new therapeutics to help combat the opioid dilemma.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB